Arabic Arabic English English French French German German
dark

MAPK4 emerges as a novel therapeutic target for triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly. In a current study published in the journal Nature Communications, a team at Baylor College of Medicine and collaborating institutions reports that MAPK4 seems to play an important role in triple-negative breast cancer (TNBC), a devastating disease with limited therapeutic options. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Madinah: Over 1,000 Beneficiaries of Medical Caravan

Next Post

Modular super-enhancer controls retinal development

Related Posts
Total
0
Share